Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Abstract

<p>Table S1. P values of comparing time to endpoint survival among all treatment groups in the LNCaP xenograft study Table S2. Summary of PSMA IHC in xenograft tumors Table S3. P values of comparing time to endpoint survival among all treatment groups in the CWR22Rv1 xenograft study Table S4. P values of comparing time to endpoint survival among all treatment groups in PC-3 xenograft study</p>